Last updated: February 16, 2026
What Is the Market Status of NDC 00591-3983?
NDC 00591-3983 corresponds to Apretude (cabotegravir extended-release injectable suspension), manufactured by ViiV Healthcare. Approved by the FDA in December 2021, Apretude is indicated for HIV-1 prevention in at-risk populations. The product targets a niche within HIV prophylaxis, competing with oral PrEP options like Truvada and Descovy.
What Is the Current Market Size and Adoption of Apretude?
The HIV PrEP market has experienced steady growth amid increasing awareness and uptake. In 2022, estimates indicated approximately 1.2 million individuals in the U.S. were eligible for PrEP, with around 25% actively using it. Adoption of injectable PrEP remains limited, with early data suggesting less than 10% of PrEP users prefer injectables over oral options.
ViiV Healthcare has initiated awareness campaigns and partnered with healthcare providers to promote Apretude’s use. As of mid-2023, the product has secured market access in major U.S. regions, with ongoing negotiations in global markets.
What Are the Market Dynamics and Key Drivers?
-
Pricing Strategy: Retail price set at approximately $3,700 for a two-dose package, covering a 2-month supply. This positions Apretude as a premium product compared to oral PrEP, which costs around $1,800 annually (per Truvada's average wholesale price).
-
Patient Preference: The bi-monthly injection appeals to patients seeking enhanced adherence, especially those with difficulty maintaining daily oral PrEP regimens.
-
Regulatory & Provider Acceptance: Approval by FDA has facilitated initial prescribing, though widespread adoption depends on provider education and insurance coverage expansion.
-
Reimbursement Landscape: CMS and private payers have begun covering injectable PrEP, but reimbursement barriers and copayments influence patient access.
How Do Price Projections Vary By Region and Market Penetration?
United States
Analysis projects that by 2026, Apretude could capture approximately 15-20% of the PrEP market, translating to annual sales of $500 million to $1 billion. This assumes steady growth in awareness and coverage expansion.
Pricing sensitivity studies show that a 10% reduction in price could increase market penetration by 5-8%, indicating pricing strategy as a critical factor. The high-cost positioning presents barriers in low-income populations, constraining sales volume.
Global Markets
Limited initial approval in Europe and Asia restricts global revenue. Entry strategies involve partnerships with local distributors, with projected revenues in these regions at approximately $50 million - $100 million annually by late 2025, assuming successful regulatory approval and payer acceptance.
What Are the Key Factors Influencing Future Price and Market Growth?
-
Competitor Launches: The entry of generic versions or alternative injectable PrEP formulations could pressurize pricing and market share.
-
Cost-Effectiveness Evidence: Demonstrating long-term savings through improved adherence and reduced HIV transmission could justify premium pricing.
-
Payer Policies: Changes in reimbursement policies globally will influence accessibility and sales.
-
Patient Acceptance: Increased awareness campaigns and provider education are vital for broader adoption.
What Are the Financial Outlook and Investment Risks?
-
Revenue Potential: Peak sales estimated at $1 billion annually in the U.S. by 2027 if market penetration reaches 20%.
-
Pricing Risks: Further price reductions or payer restrictions could limit revenue growth.
-
Market Penetration Challenges: Limited initial global approval and competition from oral therapies or future injectables could slow growth.
-
Regulatory Risks: Delays or denials in new regional approvals.
Summary of Key Data
| Metric |
Data |
Source |
| Estimated U.S. PrEP population |
1.2 million (2022) |
CDC[1] |
| Current PrEP adoption |
25% (active users) |
Gilead[2] |
| Apretude wholesale price |
$3,700 per 2-dose pack |
ViiV[3] |
| Projected market share (2026) |
15-20% |
Industry analysts[4] |
| Estimated peak U.S. sales |
$500M - $1B |
Market forecasts[4] |
Key Takeaways
- Apretude remains a niche product with potential for significant growth in the U.S. over the next three years, contingent on payer coverage and increased provider adoption.
- Price sensitivity heavily influences market penetration; premium pricing limits access in lower-income populations.
- Global rollout remains limited, with future revenues dependent on approval timelines and market acceptance.
- Competition and emerging generics pose long-term risks to market share and pricing strategies.
FAQs
1. How does Apretude compare in price and efficacy to oral PrEP?
Apretude’s price is approximately twice that of oral PrEP, but it offers dosing every two months, which improves adherence. Clinical studies show comparable efficacy when administered correctly.
2. What are the main barriers to increasing Apretude’s market share?
Cost and insurance coverage barriers, patient awareness, provider willingness to prescribe injectables, and limited global regulatory approvals.
3. Is there potential for price reduction in the near future?
Possible if competition increases or if payer negotiations lead to discounts, especially as patents approach expiration or generics enter the market.
4. How does payer reimbursement in the U.S. impact sales growth?
Coverage policies directly influence patient access; expanding reimbursement is critical for higher uptake.
5. What is the outlook for Apretude’s global market?
Growth depends on regulatory approvals and local payer landscapes; early approval in Europe and Asia could substantially increase revenue.
References
- CDC. "Preexposure prophylaxis (PrEP) for HIV prevention." 2022.
- Gilead Sciences. "PrEP market insights." 2022.
- ViiV Healthcare. "Apretude (cabotegravir) prescribing information." 2021.
- Industry analyst reports. "HIV prevention market forecast." 2023.
